Showing results (1-10 of 6) with videos related to
Sort By:
Pageof 1
Clinical Lymphoma, Myeloma & Leukemia|January 24, 2021
Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple MyelomaYael C Cohen, Albert Oriol, Ka Lung Wu, et al.British Journal of Haematology|February 8, 2021
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trialVania Hungria, Meral Beksac, Katja C Weisel, et al.British Journal of Haematology|April 6, 2021
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trialTorben Plesner, Meletios A Dimopoulos, Albert Oriol, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2022
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III TrialPieter Sonneveld, Asher Chanan-Khan, Katja Weisel, et al.Blood Advances|December 4, 2023
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUXAndrew Spencer, Philippe Moreau, Maria-Victoria Mateos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2023
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III TrialMeletios A Dimopoulos, Albert Oriol, Hareth Nahi, et al.Pageof 1